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Abstract
Background: Chlamydia prevalence remains high despite scaling-up control efforts. Transmission is not effectively
interrupted without partner notification (PN) and (timely) partner treatment (PT). In the Netherlands, the follow-up
of partners is not standardized and may depend on GPs’ time and priorities. We investigated current practice and
attitude of GPs towards PN and PT to determine the potential for Patient-Initiated Partner Treatment, which is
legally not supported yet.
Methods: Multiple data-sources were combined for a landscape analysis. Quantitative data on (potential) PT were
obtained from prescriptions in the national pharmacy register (2004–2014) and electronic patient data from NIVEL-
Primary Care Database (PCD) and from STI consultations in a subgroup of sentinel practices therein. Furthermore,
we collected information on current practice via two short questionnaires at a national GP conference and
obtained insight into GPs’ attitudes towards PN/PT in a vignette study among GPs partaking in NIVEL-PCD.
Results: Prescription data showed Azithromycin double dosages in 1–2% of cases in the pharmacy register (37.000
per year); probable chlamydia-specific repeated prescriptions or double dosages of other antibiotics in NIVEL-PCD
(115/1078) could not be interpreted as PT for chlamydia with certainty. STI consultation data revealed direct PT in
6/100 cases, via partner prescription or double doses. In the questionnaires the large majority of GPs (>95% of
1411) reported to discuss PN of current and ex-partner(s) with chlamydia patients. Direct PT was indicated as most
common method by 4% of 271 GPs overall and by 12% for partners registered in the same practice. Usually, GPs
leave further steps to the patients (83%), advising patients to tell partners to get tested (56%) or treated (28%). In
the vignette study, 16–20% of 268 GPs indicated willingness to provide direct PT, depending on patient/partner
profile, more (24–45%) if patients would have the chance to notify their partner first.
Conclusion: GPs in the Netherlands already treat some partners of chlamydia cases directly, especially partners
registered in the same practice. Follow-up of partner notification and treatment in general practice needs more
attention. GPs may be open to implement PIPT more often, provided there are clear guidelines to arrange this
legally and practically.
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Background
Chlamydia trachomatis (hereafter “chlamydia”) incidence
remains high in the Netherlands despite targeted control
efforts. The estimated report rate was 310/100,000 in
2015 and 272/100.000 in 2010. [1] STI centres provide
low-threshold additional care prioritising high-risk
groups. Young people under 25 years of age and other
high-risk groups can be tested for chlamydia without
cost at STI clinics. The general practitioner (GP) still
performs the largest number of STI consultations (esti-
mated at two thirds or more) [1]; a minority uses private
(self-)care and some get tested in the hospital (gynae-
cologist) after referral. The number of chlamydia tests
has increased over the years but diagnostic rates have
not gone down: an estimated 54,000 infections were de-
tected at GPs and STI clinics in 2015: 35,000 at the GP
and 19,000 in STI clinics. [1] New routes of chlamydia
control need to be explored and integrated in the STI
care system.
Effective partner notification (PN) and partner treat-
ment (PT) are essential to prevent re-infection and fur-
ther spread. Re-infections for chlamydia are common,
occurring in 14–20% of cases [2–5].The importance of
PN for chlamydia has been demonstrated in several
studies [6] and is addressed in all Dutch STI care man-
uals and guidelines [7, 8]. Persons notified by a sexual
partner are at high risk of infection; in Dutch STI clinics
the infection rate was 36% among women and 32%
among heterosexual men who visited due to notification
for chlamydia. [1]
Dutch guidelines advise PN for chlamydia patients (a)
in case of symptomatic infections for partners in the
period 6 weeks prior to the onset of symptoms and (b)
in case of asymptomatic infections for all partners in the
last 6 months. According to GP guidelines, [7, 8] PN
should be discussed in order to motivate chlamydia-
patients to inform their sex partners, or alternatively,
GPs should offer to help with notification or refer to
other services. The advice is to tell the partner to see a
health professional to get tested or to get treated dir-
ectly. GPs can offer presumptive treatment for a partner
presenting for consultation. Online tools for patients
and GPs are available: ‘www. Thuisarts.nl’ gives instruc-
tions on how to perform PN and ‘partnerwaarschu-
wing.nl’ [9] can be used to arrange individual PN after
diagnosis, but uptake at GPs is still limited [10].
A way to improve partner management is to provide
practical tools to simplify procedures for both patients
and GPs. A systematic review showed that providing dir-
ect treatment for the current sexual partner, so-called
Expedited Partner Therapy (EPT), can be an effective
strategy. [6] Patients give a prescription or medication to
their sexual partners to treat the infection or, alterna-
tively, partners obtain medication from the pharmacy
directly. [11] EPT is efficacious in reducing repeated in-
fections in index patients and increasing the number of
partners treated. [12–15] The implementation of EPT
reduced the chlamydia test positivity in a large scale
pilot in Washington State, USA, although this may not
have been an exclusive effect of the intervention. [16]
The method is used widely in the USA: EPT is permis-
sible in 38 states and potentially allowable in 8 states.
[17] Also in the UK, EPT or similarly, Accelerated part-
ner therapy (APT), is seen as a viable option. [18–20]
In the Netherlands, direct PT via the partner, referred
to as Patient Initiated Partner Therapy (PIPT), is not of-
ficially implemented, because a physician is legally re-
quired to have contact with a patient before prescribing
medication, to explain the reason for medication and to
check medical history and allergies. In 2016, the Project
Investigating options for Patient Initiated Contact treat-
ment for Chlamydia in the Netherlands (PICC-UP)
started, with the objective to investigate the potential of
PIPT as an effective method for improving PT. The pro-
ject covers other issues of PIPT, including the legal steps
needed for implementation. Here we describe an initial
landscape analysis on the current level of practice of
PN/PT and (potential) direct PT for chlamydia in the
general practice, as well as the attitude and opinions of
Dutch GPs towards implementation of direct PT, pro-
vided it would be possible in future. [21]
Methods
This study was set up to combine multiple sources to
explore PN/PT practices among GPs in the Netherlands,
both prescription data (paragraph 1) and questionnaire
data (paragraph 2) were used.
Quantitative data on current practice
Chlamydia-specific double dosage prescriptions as
(potential) indicator for PIPT
1.1 The SFK database (‘Stichting Farmaceutische
Kengetallen’1) contains anonymous data on
prescriptions covering 95% of public pharmacies (i.e.
extramural pharmacies) in the Netherlands.
Information is available on the date of issue,
delivered amount of tablets, average daily dose
recommended to be taken, delivered Defined Daily
Dose (DDD); the indication for the prescribed
medication is not registered in the SFK. We selected
(2004–2015) Azithromycin prescriptions typical and
thought to be exclusively used for chlamydia (single
dose of 1 g Azithromycin for 1 day or multiple dose
thereof), and calculated the proportion of double/
multiple dosage prescriptions that could reflect
simultaneous PT for chlamydia. This method had
been validated before in a previous (unpublished)
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report, showing that prescriptions of Azithromycin
single dose as specific treatment for chlamydia
compare well to estimates of the number of
chlamydia infections reported nationally.
1.2 The NIVEL-PCD was used to study episode-based
data from the electronic patient registration (2015).
This network includes over 400 practices, nationally
representative by age and gender and by population
density and geographical practice distribution.2 The
database system records data on morbidity, prescrip-
tions and referrals. Analyses were performed with
the aim to tabulate single versus double dosages with
a diagnosis code for chlamydia infection, as well as
repeated prescriptions within a period of 2 weeks
after the initial prescription, seen as (potential) cases
of PIPT. Chlamydia episodes were identified by
ICPC codes (vaginitis (X84), cervicitis (X85) and Pel-
vic Inflammatory Disease (PID) (X74) in women,
and orchitis/epididymitis (Y74) and other genital dis-
eases (Y99) in men) combined with specific
chlamydia-prescriptions, based on an earlier devel-
oped definition of chlamydia in the absence of a spe-
cific ICPC code for chlamydia. [22] Prescription data
are ATC-coded. Standard first choice treatment for
genital chlamydia is Azithromycin (1 g single dose;
ATC-code J01FA10); we also looked at dosages of
Doxycycline (2 dd 100 mg 7 days; J01AA02), given
for anal infections or epididymitis/orchitis and
Amoxicillin (during pregnancies, 3dd 500 mg 7 days;
J01CA04). We studied the dosage prescribed, based
on frequency (times per day), unit, total number of
units prescribed and whether it was a repeat pre-
scription. Episodes with one of the ICPC codes and
one of the ATC codes were selected. Episodes with
no prescription of antibiotics were assumed not to
be chlamydia; those with missing information on
dosage were excluded from the analyses.
Consultations
1.3 Sentinel practices (N = 42) of NIVEL Primary Care
Database (NIVEL-PCD), collect data specific for
STI-consultations. GPs are requested to routinely
complete a questionnaire for each registered new
disease episode in a patients’ electronic record with
an ICPC-code (International Classification of Pri-
mary Care (ICPC-1)) concerning STI/HIV issues.
This contains, with anonymous identification num-
bers, information on testing and diagnosis, patient
demographics, reason for consultation and sexual
risk behaviour. Since January 2015, questions con-
cerning PN and PT were added; we used 2015 data
for the current analyses.
Questionnaire data on current practice of PN/PT and
attitude towards PIPT
1.4 For a large pre-conference survey, GPs were asked
to fill in an online questionnaire at the time of regis-
tration for a national GP conference (November
2015). This survey included a question on partner
notification of current and ex-partners for patients
diagnosed with STIs.
1.5 At the same national GP conference, a short
questionnaire was handed out on site to GP participants.
This contained questions on the most common
methods for PN and PT in the general practice.
1.6 In the NIVEL-PCD, a vignette study on practice
and attitude of GPs towards partner management
was performed. An annual online questionnaire is
distributed among GPs in this network. We included
in this questionnaire (in 2016) two case descriptions
or ‘vignettes’, known as a useful way to measure re-
ported and/or intended physician practices in an
outpatient setting. [23, 24] The vignettes described
two hypothetical chlamydia positive patients: (i) a
‘low risk’ case, woman with a steady relationship
(25 years, Dutch; partner patient in the same prac-
tice), chlamydia probably acquired through an inci-
dental casual partner and (ii) a presumed ‘higher
risk’ case: young man (17 years, migrant back-
ground), who had 4 different female partners in the
last 4 months, and was still seeing one of these. We
asked for the GPs intention for PN and PT and his/
her attitude towards PIPT.
Results
Prescription data
1.1 In total, 443,512 chlamydia-specific prescriptions of
Azithromycin (1 g 1d) were registered in the SFK
between 2004 and 2015 (increasing, average 37,000
per year). Of these, 99.3% had a single dosage pre-
scription and 0.7% a double or (incidental) triple or
more, which may have been direct partner treat-
ment. A clear increase in double dose prescriptions
was observed from 2013 onwards: it rose from below
0.5% to 1.5% in the period 2013–2015, much more
obvious in men than in women (see Fig. 1).
1.2 For the pilot study on potential PT in the NIVEL
PCD, data from 311 general practices in 2015 was
available. We identified 18,599 episodes with one of
the five relevant ICPC codes; for a large part of
these no antibiotic was prescribed which were
therefore assumed not to be chlamydia infections
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and excluded. For 902 chlamydia episodes (in 891
patients), a total of 1078 chlamydia-related antibiotic
prescriptions were recorded with dosage information.
The major part of the prescriptions was Azithromy-
cin, a smaller part Doxycycline and a few Amoxicillin
(with specified dosages or a multiple dose thereof, see
Table 1). Double dosages were prescribed in 2.1% of
Azithromycin-treated chlamydia episodes: in 2.8% of
women and 1.3% of men (12/427 women and 5/372
men; difference not significant; 3 cases gender un-
known), most commonly in the age group 30–39 years
(3.1%; 6/191) versus 2.1% in <20 years (2/97) and 2.1%
in 20–29 years old (9/420).
Furthermore, double dosages were found for 31.1%
of Doxycycline episodes and in none of the
Amoxicillin-treated ones. The double-dosed Doxycyc-
line were prescriptions of 28 dosages instead of 14
dosages, unlikely to be PT, probably prescriptions for
2 weeks instead of 1 week, as indicated for epididymi-
tis caused by chlamydia (but duration was not consist-
ently reported). Double-dosages were indeed more
common among men than among women (46.2% of
men treated with doxycycline and 11.1% of women).
The proportion of chlamydia episodes with repeated
prescriptions was 12.6%, of which 7.6% was
registered on the same day (66/902). Of the total,
11.9% was treated with the same antibiotic and 0.8%
with a different antibiotic. These proportions did not
relate to age group or gender.
1.3 In the 42 sentinel practices, 100 chlamydia cases
were recorded in 470 STI-consultations (reported in
2015). The most common way for GPs to inform the
patient of his/her chlamydia infection was by phone
(n = 65) or personal consultation (n = 29). The
remaining cases heard it from another care provider
(under whose responsibility they were tested; n = 5)
or no follow-up was done (n = 1), as the GP stated
‘the patient had already been treated blind, so no
follow-up visit was needed’. PN was discussed with
the 94 cases contacted: most GPs (n = 85) left it to
the patient to take further steps; for two cases PN
was done by the GP or assistant, while two cases
were referred to PN services (five no answer). For 72
of the 94 cases (77%) GPs indicated they did not
treat the partner, while 12 said they advised to tell
the partner to come to the practice (13%), either for
a test (n = 6) or for direct treatment (n = 5) or both
Fig. 1 Proportion of double dosages of Azithromycin (1 g single dose) prescribed in public pharmacies in The Netherlands 2004–2015, in men
and women







Episodes with double dose N
%
Episodes with repeated Ct-
prescriptionsa
Azithromycin (1 g 1d) 937 86.9 802 88.9 17 2.1 93 11.6
Doxycycline (2dd 100 mg 7d) 123 11.4 106 11.8 33 31.1 20 18.9
Amoxicillin (3dd 500 mg 7d) 18 1.7 15 1.7 0 0 2 13.3
Total 1078 902 50 115
aepisodes had multiple prescriptions of the same or different antibiotics (maximum 4 recorded)
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(n = 1); four gave no answer. PIPT was applied in six
cases (6.4%): the GPs wrote a direct, extra medical
prescription for partners of four cases, while they
prescribed a double dosage for two cases to treat
partners simultaneously (Fig. 2). No clear correla-
tions were found between patient characteristics
(gender, sexual preference, age, reason for consult-
ation) and PN/PT.
Current practice of PN/PT and attitude towards PIPT
1.4 The online pre-conference survey was filled-in by
1411 GPs (53% of a total of 2650 conference partici-
pating GPs). The majority of GPs discusses PN of
the current partner and the ex-partner with the patient.
Of all GPs, 80% indicated to discuss PN always and 18%
mostly with their STI-patients (Fig. 3). The GPs dis-
cussed PN significantly less frequently for ex-partners
than for current partners (Chi-square p < 0.001).
1.5 The short hand-out questionnaire was completed
by 271 participants at the GP conference. The most
common method of PN reported was to discuss this
and leave it to the patient to take further steps
(83%). In most cases, the GP would advise the pa-
tient to tell his/her partner to get tested (56%) or get
treated (28%). Direct PT was used for some cases:
4% of GPs treat partners directly: 2% through pre-
scription for the partner and 2% through a double
dosage to the index. When the partner is also a pa-
tient in the same practice, 12% of GPs write a
prescription for him/her at the same time as the
index (Fig. 4).
1.6 The vignette study in the annual questionnaire to
NIVEL PCD was answered by 289 of 438 persons
(response 66%), of which we included the GPs (n =
268) for our analysis (21 questionnaires were filled
in by GP assistants or managers). The large majority
of GPs (87%) indicated they would discuss PN with
the patient and leave it to the patient to notify the
partner(s) (Table 2). PN via the MHS or another
(online) service was more commonly suggested for
the high risk than for the low risk case (74% vs
37%). PT advice was via the patient, to inform the
partner to consult a doctor to either get tested (76%)
or to get direct treatment (55%). PIPT was an option
for about one in five GPs: 16% would write a
prescription for the partner, while 6% would write a
double dosage prescription for the patient to treat
the partner simultaneously. In the hypothetical
situation that a patient could notify the partner first,
prescription for the current partner was considered
as an option, more commonly for the low risk than
the high risk case (45% vs 24%). Notification and
treatment of ex-partners or casual partners was
largely left to the responsibility of the patient. In
additional comments GPs made clear that PN/PT
steps depend on patient- and partner profiles and
the character of their relationship (e.g. steady, long-
term or casual) as well as the connection between
GP and patient.
Most of the GPs agreed PIPT can be a means to
reduce re-infections from chlamydia (62%). GPs said
to be open to the idea of PIPT: a considerable
Fig. 2 Proportion of 94 chlamydia-positive cases seen by GP for whom one of the specified partner treatments was applied (Sentinel Practices,
NIVEL PCD 2015)
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proportion of GPs indicated it should be an option
for some patients (36%), for most patients (21%) or
all (10%). Important advantages were mentioned, es-
pecially better infection control and better chances
to treat the partner, also practical ones in the sense
that it would make PT easier and cheaper. On the
other hand, a range of disadvantages were also men-
tioned. The main objections seem to lie in the uncer-
tainty whether the medication will reach the right
person and that there is no chance to give advice to
the partner or check his/her risk for allergies or
contra-indications. Furthermore over-treatment, po-
tentially leading to resistance, issues on patient priv-
acy, and the fact that the partner may have other




This first study about PN and PT of chlamydia in the
general practice in the Netherlands shows that GPs cur-
rently perform an advisory rather than active, facilitating
Fig. 3 Proportion of 1411 GPs (answering pre-conference questionnaire, Nov 2015) indicating to discuss partner notification with patients diagnosed
with an STI, for current partner(s) and for ex-partners
Fig. 4 Proportion of 271 GPs (answering ‘multiple choice’ questions at conference, Nov 2015) reporting on most common method used for
partner notification and partner treatment for patients diagnosed with chlamydia
van den Broek et al. BMC Family Practice  (2017) 18:103 Page 6 of 10
role in chlamydia PN and PT. In some cases they pro-
vide actual PIPT. In general, GPs discuss PN of current
and ex-partners with chlamydia patients but leave it to
the patient to carry it out. PIPT is applied in an esti-
mated 2–6% of chlamydia cases, based on questionnaires
and available electronic consultation- and prescription-
data. We found that when the partner is also registered
as a patient in the same practice, GPs are more inclined
to implement PIPT, i.e. in 12–21% of chlamydia cases.
PIPT for unseen/unknown partners is not yet in line
with legal regulations.
Follow-up of partner notification and treatment in
general practice needs more attention. GPs appeared to
be open to the idea of PIPT, although they also
expressed concerns, disadvantages and risks. PIPT was
an option for about one in five GPs. PN/PT intentions
may depend on the STI-risk behaviour of the patient: a
high-risk case (with multiple recent partners) would be
referred to (online) PN services more often than a low
risk case, while a low-risk case with a steady relationship
and a partner registered in the same practice was more
likely to receive PIPT, especially if the patient would
have notified the partner first. PN/PT steps also depend
on the connection between GP and patient.
Strengths and limitations
The strength of our study was the use of multiple data-
sources (questionnaires, consultation- and pharmacy data)
and the access to representative groups of GPs for ques-
tionnaire surveys (via the large national GP conference
and the NIVEL-PCD network). We have combined data
on intentions and opinions with estimates of PN/PT from
GP registers and thereby obtained much better insight
into practice and attitude towards PN and PIPT.
Some sources provided more in-depth information than
others. The questionnaires used for the (pre)conference
surveys were short and with the instruction to choose one
‘most applicable’ answer (multiple choice), more subtle
nuances may have been lost. The vignette study on the
other hand offered more room for opinions and thoughts,
giving insight in opportunities and challenges foreseen for
PIPT implementation. Intentions to use PIPT seemed
higher than actual practice, maybe due to the discrepancy
between intention and implementation but might also in-
dicate that GPs would like to apply PIPT more often but
are restricted by guidelines or regulations. Risk profiles of
patients (e.g. sexual preference) are not described in regu-
lar patient records, so the actual insight into PN/PT prac-
tice of GP’s in high risk groups was limited.
The information on PIPT from prescription data had
major limitations. The national pharmacy data showed a
small but increasing proportion of Azithromycin pre-
scribed as double dosage, but without the indication for
the medication, we cannot be certain these were for
chlamydia. Moreover, the recent update of the GP STI
guideline (end of 2013), [7] provides a 3rd choice treat-
ment option of Azithromycin 2 g single dose for gonor-
rhoea, for patients for whom Ceftriaxone is contra-
indicated and the resistance pattern unavailable. We saw
a clear rise in double dosages from 2013 onwards as well
as an unequal gender distribution of the double dosages,
which suggests these prescriptions may be for gonor-
rhoea rather than for chlamydia, because gonorrhoea is
seen more commonly in men than in women [1], due to
the sexual network (MSM) and symptomatic nature of
infections in men, urging them to visit their GP. Prob-
ably, the level before 2013 (0.4–0.5%) shows the actual
proportion of double dosages for patient and partner
prescription. In the NIVEL-PCD, part of the double/re-
peated prescriptions of antibiotics seems unlikely to be
PIPT. Double dosages of Doxycycline were prescribed in
more than 30% of cases, especially in men (46%); we
Table 2 Partner notification and partner treatment practices indicated by 289 GPs for the two ‘vignettes’ of chlamydia cases







Discuss with patient, let patient do PN him/herself 93%b 81%b 87%
Discuss and offer to do PN by GP or assistant 22% 26% 24%
Refer to MHS or use PN website 37%b 74%b 55%
Partner treatment (PT)a
Advise to get the partner to consult the GP for a test 72%b 81%b 76%
Advise to get the partner to consult a GP for direct treatment 52% 59% 55%
Prescribe antibiotics for the partner 18% 14% 16%
Prescribe a double dosage to patient to treat his/her partner 5.6% 6.9% 6.3%
Prescribe AB to partner after patient has done PN 45%b 24%b 34%
amultiple choice questions, more than 1 answer possible
bsignificant difference between low risk and high risk, at p < 0.05. PN = partner notification; PT = Partner Treatment
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suspect these relate to other diagnoses including (acute)
epididymitis or PID, for which a prolonged course is in-
dicated. The repeated prescriptions on 1 day may also
have been registration artefacts, due to back reporting
from pharmacies after patients receive the medication.
Hence, to be able to use prescription data to monitor
PIPT, more reliable information on the prescription and
its indication is required. The registration in the national
pharmacy database would be improved by including the
indication of prescriptions. Prescription data from the
GP electronic patient registration would be improved by
adapting software to extract more exact dosage schemes
and clarifying whether or not back-reporting from the
pharmacy takes place in the one or more of the current
registration software systems in use.
Comparison to other studies and countries
We found that the implementation of PIPT for chla-
mydia is currently low among GPs in the Netherlands,
while GPs showed a higher intention to use PIPT when
presented with hypothetical chlamydia cases and after
PIPT principles were explained briefly. The low level is
not surprising, as in the current legal system in the
Netherlands the GP should have contact with the part-
ner, before prescribing antibiotics, to check medical his-
tory and allergies and inform about the reason for
prescription. [25] In fact, some of the cases of PIPT in
the records may have been given without observing the
law. In other countries where PIPT is legal, levels of up-
take are still relatively low: in the US, in a national sur-
vey of more than 3000 physicians who treat patients for
STIs, approximately 50% reported ever using PIPT, while
only 11%–14% of physicians reported usually or always
using PIPT. [26] In New York City, the number of expe-
dited partner therapy prescriptions was found to be low
and vary greatly between pharmacies in New York City.
[27] In the UK, in a pilot RCT the proportion of part-
ners treated after partner details (medical history and al-
lergies) were communicated via the phone (35%) or at
pharmacy (46%) did not exceed that by standard patient
referral (45%). [18]
In our vignette study, GPs have shown to be aware of
the beneficial effects of PIPT in preventing further trans-
mission and facilitating partner management procedures
for chlamydia, as has been assessed in effectiveness stud-
ies in other countries (US [13–16], UK [28]) and reviews
reporting an overall 20–29% reduction of reinfection. [6,
29, 30] Besides the effect on transmission, PIPT can sim-
plify procedures for the partner, which will make treat-
ment much faster. The few cases that may receive PIPT,
according to the present study, appear to be at relatively
low risk, with a steady partner who is patient in the
same practice. Successful treatment of current partners
is most important for preventing reinfection of index
cases and reducing further transmission of chlamydia at
the population level. On the other hand, also for casual
partners, or when it is likely that partners will not seek
treatment and are at high risk of infection, PIPT is a
good last option or ‘better than nothing’ [31]. Modelling
studies by Althaus [32, 33] showed that PN for partners
up to 18 months back would identify 10% infections in
notified partners.
The GPs in our study also mentioned important barriers
to implement PIPT, which have been reported in the lit-
erature as well. [30, 31] GPs stated in the questionnaire
that PIPT reduces the opportunity for the partner to see a
professional and get further STI counselling and advice.
[34] Current legislation requires direct contact with part-
ners. It remains unclear if contact by telephone is suffi-
cient to meet the legal requirements for the prescription
of a drug. It is defendable that under certain conditions
contact by telephone with a partner will suffice, but the
applicable law nor the existing case law gives a decisive
answer to that question. Contacting partners via internet
would however certainly require a change in legal require-
ments. Current GP guidelines on partner notification
should be extended with a specification of how and when
PIPT can be applied (for partners in the same practice
and/or when timely treatment is impossible without
PIPT). A further concern is that the patient may not reach
his/her partner(s) so partner uptake is not guaranteed.
[19, 35] The partner may have other STIs or have sexual
contact with other partners, which would not be traced
with PIPT. [36] Potential over-treatment by PIPT is a real
concern, as only 35% of those notified for chlamydia are
found infected. [1] Following antibiotic stewardship, care-
ful use of antibiotics is advocated and embedded in the
Dutch habit of relatively low use of antibiotics in patient
care in general (the lowest in Europe [37]). Resistance of
chlamydia to Azithromycin is not an urgent threat, [38]
but for gonorrhoea, a common co-infection with chla-
mydia which could go unnoticed with PIPT, it is on the
rise. [39] Furthermore, in case of an anal (co)infection,
chlamydia should be treated with Doxycycline and not just
Azithromycin. [7, 8]
Conclusions/recommendations
GPs in the Netherlands are open to implement PIPT for
some chlamydia cases but not for all, provided there are
clear guidelines, including clarity about legal options,
and indications how PIPT can be applied and which pa-
tients and partners would be eligible for PIPT. We ad-
vise recommendations for partner treatment in GP
guidelines to be extended with a specification of when
and how PIPT can be applied.
Endnotes
1See: https://www.sfk.nl/english (accessed may 2017)




APT: Accelerated Partner Therapy; ATC: Anatomical Therapeutic Chemical
classification system; EPT: Expedited Partner Therapy; GP: General Practitioner;
ICPC: International Coding Primary Care; MHS : Municipal Health Services;
PIPT: Patient Initiated Partner Therapy; PN: Partner Notification; PT: Partner
Treatment; STI: Sexually Transmitted Infection
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